BEAT Upbeat, SYRS Gearing Up For ASH, Catalyst-Rich Year Ahead For ARGX

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of November 30, 2017.

GAINERS

1. Verastem Inc. (VSTM)

Gained 15.03% to close Thursday’s (Nov.30) trading at $4.21.

News: No news

The Company’s lead product candidate is Duvelisib.

Near-term catalysts:

— Initiation of a phase II study of Duvelisib in patients with relapsed or refractory *PTCL is expected by year end.
— Submit NDA for Duvelisib during the first quarter of 2018, requesting full approval for it for the treatment of patients with relapsed or refractory *CLL/SLL and accelerated approval for the treatment of patients with relapsed or refractory FL.

* Peripheral T-cell lymphoma (PTCL); Chronic lymphocytic leukemia (CLL); Small lymphocytic lymphoma (SLL); Follicular lymphoma (FL).

2. argenx SE (ARGX)

Gained 14.32% to close Thursday’s trading at $32.02.

News: No news

Pipeline:

The Company’s most advanced product candidate is ARGX-113. Three phase II trials with an intravenous formulation of ARGX-113 are underway – one in patients with myasthenia gravis, another in patients with primary immune thrombocytopenia, and the third in patients with pemphigus vulgaris.

We had alerted our premium subscribers to ARGX on November 23, 2017.

3. Syros Pharmaceuticals Inc. (SYRS)

Gained 12.59% to close Thursday’s trading at $14.85.

News: No news

Pipeline:

The Company’s drug candidates are SY-1425, in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers.

Near-term catalysts:

— Initial clinical data from phase II clinical trial of SY-1425 are expected to be reported on December 10, 2017.
— Preliminary clinical data from phase I clinical trial of SY-1365 is expected in 2018.

4. Sangamo Therapeutics Inc. (SGMO)

Gained 12.11% to close Thursday’s trading at $16.20.

News: No news

The company’s proprietary technology is “zinc-finger protein”, or ZFP, technology, which is designed to edit DNA, say by turning off or turning on genes for treating a disease. Zinc finger proteins are a class of naturally-occurring DNA binding proteins, and they are so named because they resemble a finger-like shape and include a zinc ion.

Recent event:

— On November 15th, the Company reached an important milestone – i.e., the dosing of the first…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *